Celgene v. Eurofarma: São Paulo Appeal Dismissed in Lenalidomide Patent Dispute
Celgene Corp. pursued an infringement action against Eurofarma Laboratórios before the Court of Justice of São Paulo, asserting Brazilian patent BRPI0315315B1 covering the use of lenalidomide for treating myelodysplastic syndrome. The appellate court denied the appeal, closing the matter without a merits ruling at this level.
Celgene’s Lenalidomide Appeal Denied in Brazilian Infringement Dispute
Celgene Corp., the originator holder of Brazilian patent BRPI0315315B1, brought an infringement action against generic pharmaceutical manufacturer Eurofarma Laboratórios S/A before Brazilian courts. The patent in suit protects the use of lenalidomide — marketed as Revlimid — specifically for the preparation of a medicament for treating myelodysplastic syndrome (MDS), a serious haematological condition. The dispute was heard at the Court of Justice of São Paulo, one of Brazil’s principal state appellate courts handling complex IP matters.
The Court of Justice of São Paulo dismissed the appeal on 22 October 2025, recording the outcome as ‘Deny Appeal granted’ — Brazilian procedural language indicating the appellate panel voted to deny the appeal brought before it. The basis of termination is recorded as ‘Appeal Dismissed,’ meaning the court did not reach or resolve the underlying infringement merits at this appellate stage. The precise procedural grounds for dismissal — whether substantive or technical — are not detailed in the publicly available record.
The absence of a filed date in the public record makes it impossible to calculate the full duration of the appellate proceedings. What is notable is that lenalidomide remains one of the most commercially significant pharmaceutical patents globally, and Brazilian generics challenges to Celgene’s (now Bristol Myers Squibb’s) MDS indication have attracted sustained litigation interest. Whether Eurofarma or Celgene pursued further avenues following this dismissal is not confirmed in the available public record.
Filing to Appeal Dismissed in 0 days
Case closed 22 October 2025 by the Court of Justice of São Paulo
Appeal dismissed: what the São Paulo ruling means for both parties
Appeal dismissed without merits adjudication
A dismissal of an appeal at the Court of Justice of São Paulo means the appellate panel declined to proceed with a substantive review of the lower court’s findings. The phrase ‘Deny Appeal granted’ reflects Brazilian procedural convention: the panel voted to deny the appeal, effectively leaving the prior decision in place. Critically, this is not a ruling on the underlying infringement claim — it is a procedural termination at the appellate level.
No merits ruling issuedCelgene’s appellate position closes without resolution
Where Celgene was the appellant, the dismissal means its appeal did not advance. Where Eurofarma was the appellant, dismissal favours Celgene by preserving the lower court’s position. The public record does not specify which party filed the appeal, leaving the net effect on patent enforceability for BRPI0315315B1 uncertain from the available data. Celgene’s (now BMS’s) commercial position in the Brazilian MDS market may remain contested through separate proceedings.
Enforceability status unclearEurofarma’s appellate path terminates at this level
For Eurofarma, a dismissed appeal — if Eurofarma was the appellant — closes this particular procedural avenue without securing a merits ruling in its favour. Brazilian procedural rules may allow further challenge routes, including to the Superior Court of Justice (STJ) on points of law, but the bar for such escalation is high. Without a merits finding of non-infringement or invalidity, Eurofarma’s commercial freedom to operate with lenalidomide in MDS indications remains legally uncertain.
FTO position unresolvedBrazilian lenalidomide market remains under IP pressure
Brazil’s pharmaceutical generics sector closely watches lenalidomide litigation given Revlimid’s multi-billion dollar global revenues. A dismissed appeal without merits adjudication leaves BRPI0315315B1’s enforceability in an ambiguous state for market participants. Generic entrants and biosimilar developers targeting the MDS indication in Brazil should treat this case as a signal that Celgene/BMS will contest infringement actively, and that procedural barriers in Brazilian appellate courts can delay definitive outcomes.
Brazilian pharma IP risk elevatedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Celgene, Corp. | Company | Originator pharmaceutical company — holder of BRPI0315315B1 for lenalidomide in MDSSearch in Eureka ↗ |
| Defendant | EUROFARMA LABORATÓRIOS S/A | Individual | Brazilian generic pharmaceutical manufacturer Eurofarma Laboratórios S/ASearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Justice of Sao PauloSearch in Eureka ↗ |
Official order — verbatim text
The verdict text — ‘Before the above, Deny Appeal granted’ — reflects standard Brazilian appellate panel language recording a majority or unanimous vote to deny the appeal in question. This is a procedural disposition: the court closes the appellate proceeding without examining or ruling on the merits of the underlying infringement claim. Neither infringement nor non-infringement is established by this outcome, and patent BRPI0315315B1’s enforceability against Eurofarma is not definitively resolved at this level.
BRPI0315315B1 — Lenalidomide Use in Myelodysplastic Syndrome
Brazilian patent BRPI0315315B1 protects the use of lenalidomide — chemically identified as 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione — or a pharmaceutically acceptable salt thereof, specifically for preparing a medicament to treat myelodysplastic syndrome (MDS). MDS is a group of disorders caused by poorly formed blood cells and covers a therapeutic area with significant unmet need. The ‘B1’ grant designation confirms the patent has been examined and granted by Brazil’s INPI. The patent traces its priority to Celgene’s international filing activity in the early 2000s, consistent with the broader Revlimid patent family.
BRPI0315315B1 is part of one of the most commercially defended pharmaceutical patent portfolios globally. Lenalidomide generated over USD 12 billion in annual revenues for BMS/Celgene at peak, and the Brazilian market represents a growing frontier for both branded and generic competition. For competitors, the MDS-specific use claim is narrow but strategically vital: any generic seeking ANVISA approval for lenalidomide in MDS indications must navigate this patent. The case against Eurofarma — Brazil’s largest domestically owned pharmaceutical group — suggests the enforceability of this patent remains actively contested in the Brazilian market.
Should your team run an FTO against BRPI0315315B1?
Any company developing, manufacturing, importing, or distributing lenalidomide-containing products in Brazil for the treatment of myelodysplastic syndrome should treat BRPI0315315B1 as a live risk. The appeal dismissal in this case does not resolve underlying enforceability — it leaves the patent’s status contested but not invalidated. R&D teams working on lenalidomide formulations, combination therapies, or adjacent haematological indications under similar chemical scaffolds should commission a Brazil-specific FTO before any commercial or regulatory filing.
PatSnap Eureka’s FTO Search Agent can map BRPI0315315B1 against your product’s claims, identify the remaining claim scope after any prosecution history, surface related patent family members active in Brazil, and flag INPI administrative challenge history. For Brazilian pharmaceutical market entry, Eureka can also cross-reference ANVISA’s patent linkage list and alert you to parallel litigation activity involving the same patent family — giving your legal and commercial teams a single intelligence view before committing to market entry.
Run a freedom-to-operate analysis on BRPI0315315B1 to assess your product’s exposure
Run FTO in Eureka →Similar Lenalidomide & Brazilian Pharma Patent Infringement Cases
Cases involving lenalidomide patent enforcement, Brazilian pharmaceutical infringement actions, and MDS indication IP disputes before São Paulo and federal courts.
What this case signals for the Brazilian pharmaceutical patent landscape
Lenalidomide patent disputes in Brazil reflect a broader tension between originator IP enforcement and generic market access in a high-value therapeutic area.
Brazilian appellate dismissals do not resolve underlying patent validity
A dismissed appeal at the Court of Justice of São Paulo leaves the merits of both infringement and validity untouched. For any company monitoring BRPI0315315B1’s status in Brazil, this outcome should not be read as confirmation of either enforceability or freedom to operate. Independent FTO analysis remains essential before any commercial step in the Brazilian MDS market.
Lenalidomide IP in Brazil is subject to multi-front enforcement strategy
Celgene and its successor BMS have demonstrated willingness to pursue infringement actions in Brazilian courts across multiple jurisdictions and patent families. Companies developing or distributing lenalidomide formulations in Brazil — whether for MDS, multiple myeloma, or adjacent indications — should map all relevant Brazilian patent rights and monitor litigation activity through a unified IP intelligence platform.
Celgene v EUROFARMA — key questions answered
The Court of Justice of São Paulo dismissed the appeal on 22 October 2025, recording the outcome as ‘Deny Appeal granted.’ This is a procedural termination — no merits ruling on infringement or validity of patent BRPI0315315B1 was issued at this appellate level.
BRPI0315315B1 is a Brazilian granted patent (B1 = examined grant) protecting the use of lenalidomide — or a pharmaceutically acceptable salt — specifically for preparing a medicament to treat myelodysplastic syndrome (MDS). It is part of Celgene’s (now BMS’s) global Revlimid patent portfolio and was the subject of an infringement action against Eurofarma Laboratórios S/A.
No. An appeal dismissal at the Court of Justice of São Paulo is a procedural outcome that does not adjudicate infringement or validity. The patent’s enforceability against Eurofarma remains legally unresolved on the merits from this case alone. Parallel proceedings or future actions may still determine the substantive question.
Potentially. Under Brazilian procedural law, parties may seek review at the Superior Court of Justice (STJ) on points of federal law following a state court of justice decision. Administrative challenges to the patent before INPI may also be available. The specific post-dismissal options depend on procedural grounds not fully detailed in the available public record.
Lenalidomide (Revlimid) generated peak annual revenues exceeding USD 12 billion globally for Celgene/BMS, and MDS is a key indication. Brazil’s growing pharmaceutical market and ANVISA’s regulatory framework create strong incentives for generic entry. Eurofarma is Brazil’s largest domestically owned pharmaceutical company, making this dispute a bellwether for how originator IP is enforced against major local generics players in high-value haematology therapeutics.
PatSnap Eureka searches patents and litigation data to answer instantly.